| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8458803 | Radiotherapy and Oncology | 2018 | 6 Pages |
Abstract
The findings of this study show that HDR-BT 13.5â¯Gyâ¯Ãâ¯2 as monotherapy was safe and effective for prostate cancer patients with low-intermediate risk.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Gorka Nagore, Jose Luis Lopez Guerra, Evita Krumina, Mark Lagos, Beatriz Ovalles, Antonio Miró, Lourdes Beltran, Emilia Gómez, Juan Manuel Praena-Fernandez, Eleonor Rivin del Campo, Ignacio Azinovic, Alfonso Gomez-Iturriaga,